Samsung has joined the latest round of funding for Swedish fertility tracking app Natural Cycles, as it looks to bring women’s health technology to its Galaxy smartwatches.

Natural Cycles which monitors body temperature to gauge fertility in 2018 became the first contraceptive of its kind approved by the US Food and Drug Administration.

Samsung plans to launch the app on Galaxy Watch5 devices in the second quarter, and its investment is part of Natural Cycles Nordic AB’s $7 million funding round.

The company, founded by physicist Dr Elina Berglund and her husband Dr Raoul Scherwitz, raised a “modest” amount as it prioritized attracting strategic partners to help expand the number of tracking options.

The app has more than two million users worldwide. Owners of the Oura smartwatch have been able to use the app since August, and in September Apple introduced its own ovulation tracking feature on its Apple Watch devices.

In the U.S., the company’s largest market today, reproductive rights and privacy issues have come under the spotlight since the Supreme Court last year overturned the landmark Roe v. Wade decision on abortion access that led to reproductive health bans and restrictions, as well as concerns about the privacy of personal data.

According to Raoul Scherwitzl, Natural Cycles is “well-prepared to operate in a post-Roe v. Wade” environment with strong privacy protections in place due to it being a regulated medical device.”

“With many contraceptives only available by prescription, Natural Cycles’ over-the-counter availability puts it in a unique position and is why we continue to see a high level of growth,” he said.